Status:
COMPLETED
Comparative Evaluation of the Evolution of Emerging Biological Markers in Patients Hospitalized for Acute Heart Failure According to Conventional Management or Therapeutic Adjustment Via Daily Ultrasound.
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
This is a bi-centric, prospective randomized study to evaluate the contribution of rapid echocardioscopy at the patient's bedside to improving the prognosis of patients hospitalized for acute heart fa...
Detailed Description
The JECICA study is the first prospective randomized study to evaluate the contribution of rapid echocardioscopy at the patient's bedside to improving the prognosis of patients hospitalized for acute ...
Eligibility Criteria
Inclusion
- Inclusion Criteria: (General inclusion criteria)
- The patient or his representative must have given free and informed consent and signed the consent form.
- The patient must be affiliated to or beneficiary of a health insurance plan.
- The patient must have been available for 6 months of follow-up.
- The patient is at least (\>) 18 years of age.
- Inclusion criteria for target population:
- Patient hospitalized for acute heart failure who received at least 40mg of IV furosemide.
- Patient with impaired Left Ventricle Ejection Fraction \<50%.
- Patient with an Nt-ProBNP value \>1200pg/ml.
- Exclusion Criteria : (General non-inclusion criteria)
- Subject is participating in another study.
- Subject is in an exclusion period determined by a previous study.
- Subject is under court protection.
- Subject or subject's representative refuses to sign consent.
- It is not possible to provide the subject or the subject's representative with informed information.
- Criteria for non-inclusion regarding associated interfering diseases or conditions:
- Patient is pregnant or breastfeeding.
- Patient is already included in a surveillance program (PRADO, OSICAT).
- Patient has a mechanical or biological mitral prosthesis.
- History of mitral narrowing.
- Severe valve disease with a surgical deadline within a month (\<30 days).
- Chronic renal failure on dialysis.
- High grade BAV (BAV 2/1 and BAV3).
- Hypertrophic cardiomyopathy.
- Cardiogenic shock.
- Contraindication to furosemide.
- Anechoic patient.
- Exclusion criteria:
- \- Patient hospitalized for more than (\>) 1 month.
Exclusion
Key Trial Info
Start Date :
February 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 9 2022
Estimated Enrollment :
169 Patients enrolled
Trial Details
Trial ID
NCT05297630
Start Date
February 15 2022
End Date
July 9 2022
Last Update
July 27 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Nîmes University Hospital
Nîmes, Gard, France, 30029
2
Montpellier University Hospital, Arnaud de Villeneuve
Montpellier, Hérault, France, 34295